It is known that an increased oxidative stress is present in a wide range of diseases and, given the vulnerability of the central nervous system, its involvement has been in particular investigated in neurological and psychiatric diseases, including anxiety disorders. In this review we analyse the studies that have been conducted on the effects of oxidative stress modulators in 
Introduction

Anxiety disorders
Anxiety disorders are the most common class of psychiatric disorders [1, 2] . The Diagnostic and Statistical Manual of Mental Disorders (DSM-5) divides them in: separation anxiety disorder, selective mutism, specific phobia, social phobia, panic disorder, agoraphobia, generalized anxiety disorder, anxiety disorder caused by use of substances, and anxiety disorder due to another medical condition [3] .
Many epidemiological studies have shown that anxiety disorders typically start in childhood or in early adult age and tend to decrease in older age, with a median age of onset of 11 years [4] , and in the absence of proper treatment they can become chronic. Anxiety disorders in Europe have a twelve months and a lifetime prevalence of 8,4% and 14,8%, respectively, with prevalence being approximately twice higher in women than in men [5] .
They cause more loss of working days than other disorders of high social impact, with an economic burden of 41 billion Euros in the EU in 2004 [5] .
Anxiety disorders are often in comorbidity with other psychiatric conditions, such as depressive disorders, drug and alcohol abuse, personality disorders, bipolar disorder [6] and also with chronic medical conditions, such as diabetes [7] ,chronic obstructive pulmonary disease [8] , thyroid dysfunction [9] and coronary artery disease [10] .
Amygdala and the insular cortex play a crucial role in the pathophysiology of anxiety [11] ; these brain regions are activated in response to fear in healthy individuals, and are hyperactive during the processing of negative emotions in patients with anxiety disorder [11] .
Although different theories have been proposed, the etiology of anxiety disorders is still unclear [12] . One theory suggests an association between the biochemical alterations caused by oxidative stress and anxiety, although a causal relationship between oxidative stress and anxiety has not been demonstrated, as yet.
Oxidative Stress
Oxidative stress is determined by the excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS) [13] . Their deleterious action on proteins, DNA and lipids causes cell damage.
Production and cellular effects of ROS
The main cellular source of ROS is the mitochondrial respiratory chain, which is composed by five multisubunit protein complexes, and utilizes nicotinamide adenine dinucleotide (NADH), flavin adenine dinucleotide (FADH2), coenzyme Q (CoQ), and cytochrome c (Cyt c)as electron donors [14] .
Electrons are transferred one by one from the respiratory chain to O2, leading to the formation of superoxide anions (O2 -. ), which may leave the respiratory chain and can generate additional ROS species by interacting with other molecules [15] . NADPH-oxidase (NOX), xanthine oxidase (XO), cyclooxygenase, lipoxygenase, epoxygenase, and cytochrome-P450 are additional sources of O2 -. [16] . O2 -. can be converted into hydrogen peroxide (H2O2) by copper-zinc superoxide dismutase (SOD1) in the cytosol and manganese superoxide dismutase (SOD2) in the mitochondria. [14, 17] .
Hydroxyl radicals are powerful oxidizing agents, that can damage proteins, lipids, sugars and DNA [16] .
RNS and their cellular effects
The RNS, nitric oxide (NO . ) and peroxynitrite (NOOO -), have gained popularity as intracellular and intercellular mediators, and may also cause cellular damage. Nitric oxide (NO) is synthesized from Larginine by NO synthase (NOS) isoenzymes [18] . NO can compete with SOD for O2 -. , forming NOOO -, which can nitrosylate tyrosine residues in proteins [19] leading to structural and functional protein changes [20] ; NOOO -can also cause lipid peroxidation and apoptotic death [21, 22] .
Lipid peroxidation and its products
Lipid peroxidation caused by ROS or RNS, represents a common mechanism of lipid damage. In this particular process, oxidants attack the lipids containing carboncarbon double bonds, like polyunsaturated fatty acids (PUFAs), glycolipids, phospholipids and cholesterol [23] . Lipid peroxidation is a chain reaction that once started continues until the formation of the final products. Lipid hydroperoxides are the main primary products of lipid peroxidation; alkens, ketones, and reactive carbonyl compounds are secondary products (RCCs) [23] . They include aldehydes, such as malondialdhyde (MDA) and 4-hydroxynonenal (4-HNE), and α-oxalaldehydes, such as glyoxal and methylglyoxal [24, 25] . These compounds may cause cytoxicity by promoting the formation of end glycation products or by damaging DNA, proteins, and membrane lipids [26] .
Oxidative stress and anxiety in animal models
In preclinical studies, caused an increased anxiety-like behaviour, whereas a reduced anxiety was seen after Glio1 gene silencing [30] . In contrast, Krömer et al., using outbred CD1 mice, found an association between low level of anxiety and increased expression of Glo1 in the hypothalamus, amygdala and motor cortex [31] , and in peripheral red blood cells [32] .
A study by Williams et al. shows evidence that variability of Glo1 expression in mice is the result of a common duplication of a large genomic region including the Glo1 gene. Gene duplication is associated with increased Glo1 expression and anxiety-like behaviour both in inbred and outbred CD1 mice [33] , in agreement with findings obtained by Hovatta et al. [30] .
It has been proposed that methylglyoxal induced neuronal damage may be a critical determinant in the high-or low-anxiety behaviour seen in different studies.
[34]
Using transgenic mice, Distler et al. found that
Glo1caused an anxiolytic effect by reducing the formation of methylglyoxal, thereby activating GABAA receptors [35] . Moving from these findings, it has been proposed that Glo1 may represent a putative drug target in the treatment of anxiety disorders [36] , although the precise role played by Glo1 in the pathophysiology of anxiety should be the subject of further investigation [35] . Hassan et al used two lines of rats, characterized by a different freezing response to fear conditioning, named "Carioca high-and low-conditioned freezing"(CHF and CLF). In the CHF line, the concentrations of free radicals and MDA were higher in the hippocampus, cerebellum, and cerebral cortex, CAT activity was decreased in hippocampus and cortex, and GPx activity was decreased in all three structures, as compared to the CLF line [42] .
A following study showed that administration of diphenyl diselenide, a compound endowed with antioxidant propriety, caused a reduction of freezing in anxious rats [43] .
In rats, exposure to a predator odor caused an increased ROS production and SOD activity in the amygdala, and an increase in SOD activity only in the prefrontal cortex and hypothalamus [44] . In another study in which exposure to predator odor was associated to psychosocial stress, ROS levels were significantly elevated in the hippocampus and prefrontal cortex of stressed animals [45] .
The role of RSN in anxiety was examined in a model of social isolation. Nitrite levels were increased in the hippocampus and cortex of stressed mice, and administration of NOS inhibitors reversed anxiety-like behaviour induced by social isolation [46] . Increased nitrosative stress was also found in restrain stress model of anxiety [47] .
Oxidative stress in patients with anxiety and other psychiatric disorders
The Central Nervous System (CNS) is highly vulnerable to oxidative stress for the following reasons [48] : (i) the brain has a high oxygen consumption (about 20% of the assumed oxygen) [49] ; (ii) neuronal membranes are rich in PUFA, which are susceptible to lipid peroxidation and, (iv) intracellular iron accumulates in neurons of the aged brain [52] .
The knowledge that the human brain is particularly vulnerable to oxidative stress stimulated the search for peripheral markers of oxidative in the blood of patients with psychiatric disorders, such as anxiety [49] . A clinical study evaluated oxidative stress in patients with generalized anxiety disorder (GAD), by measuring the total oxidative status (TOS), the total antioxidant status (TAS) and the ratio between TOS and TAS, which is the oxidative stress index (OSI). They found that TOS and OSI were significantly higher in patients affected by GAD than in healthy controls, while TAS was lower [53] .
Increased levels of lipid peroxidation markers have also been found in patients with anxiety disorders [13] .
Atmaca et al found increased MDA levels, and an increased activity of SOD, CAT, and GPx in patients with social phobia [54] . Increases in MDA levels, depletion of GSH, vitamins A and E, and increased SOD and GPx activity were found in patients suffering of panic attacks [55, 56] . In contrast, Hagan et al., in a cross-sectional study of 1,325 women, did not find an association between phobic anxiety and plasma fluorescent oxidation products (FLOPs), which are nonspecific markers of global oxidative stress originating from the interaction of ROS with macromolecules [57] .
In children with anxiety disorder Ceylan et al. found
higher serum levels of lipid hydroperoxide (LOOH) as compared to healthy controls with no changes in the activity of the antioxidant enzymes, paraoxonase and arylesterase [58] . A similar increase in plasma LOOH levels was reported in adult patients affected by GAD.
These patients also showed a reduced activity of paraoxonase [59] . 
Oxidative stress modulators
Despite OS is only one of the multiple mechanisms has been associated to chronic neurological diseases [62] . Data obtained in experimental animals suggest that the Nrf2 pathway plays a role in anxiety disorders.
Intracerebroventricular injection of Nrf2 siRNA in adult
Wistar rats increased anxiety-like behaviour associated with an increased Bax/Bcl ratio in the hippocampus, amygdala, and prefrontal cortex [63] . Nrf2 activation has been shown to be a common mechanism of action of several antioxidants, such as curcuminoids, quercetin, epigallocatechin gallate, resveratrol, N-acetylysteine and ebselen. However, the risk-to-benefit ration should be carefully evaluated when using Nrf2 activators. For example, Nrf2 activation may promote tumour growth and cancer cell resistance to chemotherapy [64] .
Another indirect antioxidant mechanism is the modulation of the activity of sirtuins, a family of seven proteins (SIRT1-7) that act as epigenetic regulators, and are involved in a wide range of cellular processes, including oxidative stress [65] . In particular, SIRT1 and SIRT3 are primarily involved in OS regulation [66] . Quercetin was also effective in reducing stress-induced depression and the associated increase in hypothalamic corticotropin-releasing factor (CRF) mRNA levels [72] .
It has been hypothesized that quercetin restrain the anxyogenic and pro-depressant effects of CRF [73] .
Accordingly, quercetin and the CRF receptor antagonist, antalarmin, produced synergistic anxyolitic and antidepressant effects perhaps through the modulation of OS [74] .Quercetin administration was also shown to be protective against toxicity induced by heavy metals, such as aluminium [75] or cadmium [76] . Exposure to both agents caused a reduction in acetylcholinesterase (AChE) activity and ATP levels in the rat brain andan impairment in cognitive and behavioural tasks associated with an increased anxiety-like behavior.
Quercetin treatment could reverse all these pathological changes. The effects of quercetin were ascribed to its ability to reduce OS, thus protective cell membranes and associates enzymes against oxidative damage.
Quercetin has been shown to rescue anxiety-like behaviour also in a model of neurotoxicity induced by polychlorinated biphenyls (PCBs) in adult rats.
Quercetin also reduced PCB-induced ROS formation, hippocampal damage, and abnormalities in neurotransmitter levels [77] .
Other studies have shown that the anxiolytic and procognitive effects of quercetin are associated with changes in brain levels of GABA [78] and serotonin [79] . Quercetin, like other flavonoids, acts also as a
Monoamino Oxidase A inhibitor [80] [81] [82] [83] .
Ginkgo biloba: EGb 761 and ginkgolides
Ginkgo biloba is a very ancient plant, and its fruits, seeds, and leafs have been widely used by traditional medicine [84] . Currently the extract EGb 761 of Ginkgo biloba leaves is primarily used to improve memory and other potential therapeutic uses are under investigation.
The extract has numerous pharmacological activities mediated, inter alia, to terpenes and flavonoids.
Animal studies have shown that EGb 761 displays antidepressant/anxiolytic effects, described as antistress or stress-alleviating [85] . Some studies have found that curcumin is also endowed with anxiolytic activity.
Interestingly curcumin reverses anxiety-like behaviour caused by acute lead exposure [96] and acute immobilization stress [97] . Interestingly, acute stress was associated with lipid peroxidation, increased SOD activity, decreased CAT activity, and a compensatory increase in GPx activity. Curcumin treatment corrected all these abnormalities, raising the interesting possibility that antioxidants may be useful for the treatment of stress-induced anxiety.
The anxiolytic-like effect of curcumin in rats was also shown by Patel et al, who showed that curcumin has synergistic effects with amitriptyline in relieving depression and anxiety [98] .
Curcumin was shown to enhance docosahexaenoic acid (DHA) synthesis in liver cells and to up-regulate the expression of DHA-synthesizing enzymes in the liver and brain when combined with dietary α-linolenic acid.
Interestingly, this effect was related to the anxiolytic activity of curcumin [99] . Other studies suggest that the anxiolytic activity of curcumin cannot be exclusively explained by its antioxidant properties, but involves additional mechanisms, such as changes in monoamine levels in the CNS [100] . Accordingly, curcumin treatment could reverse changes in monoaminelevels induced by olfactory bulbectomy, which is a validated animal model of depression [101] .
The antianxiety-like effect of curcumin has also been shown in mice. Gilhotra and Dhingra showed that curcumin, at a dose of 20 mg/kg, produced antianxietylike effects in mice exposed to restraint stress. The action of curcumin was potentiated by pretreatment with the iNOS inhibitor, aminoguanidine, but not with the nNOS inhibitor, 7-nitroindazole [102] . This study moved from the evidence that curcumin relieved anxiety and attenuated oxidative damage induced by sleep deprivation in mice. These effects were prevented by the nitric oxide precursor, L-arginine, and were potentiated by the NOS pseudosubstrate, L-NAME [103] . there was a significant difference in the heart rate between the two groups [119] . This clinical trial further supported the anxiolytic effect of Vitamin C in humans.
Vitamin E
Vitamin E (α-tocopherol) is a lipid soluble antioxidant that also act terminating the lipid peroxidation chain reaction.
Both animal that human studies have shown that a chronic severe deficiency of vitamin E determines the onset of ataxia [120] [121] [122] .This finding generated further studies on the effects of vitamin E deficiency [123] .
A study by Goheil showed that, in α-Tocopherol
Transfer Protein (α-TTP) knock-out mice, it also occurred a decrease in some behavioural parameters Therefore, anxiety related to vitamin E deficiency seemed to be linked to increased oxidative stress and elevated corticosterone plasma concentrations [120] .
However in other studies the α-tocopherol has been reported to be anxiogenic in Wistar rats at the EPM test [125, 126] . This could be due to a different action of vitamin E from the antioxidant effect.
Thiol agents 4.4.1 N-acetylcysteine (NAC)
N-acetyl cysteine (NAC) is a derivative of the amino acid cysteine [127] , with initial main indication as an antidote to paracetamol intoxication, as a mucolytic agent in chronic obstructive pulmonary disease and cystic fibrosis and as a renal protector in contrastinduced nephropathy [128] . Over the past decade it has also been paid much attention to the use of NAC in the treatment of neuropsychiatric disorders [129] . Among the actions exerted by NAC in these disorders, there is the antioxidant one. NAC has a weak direct antioxidant effect due to the presence of a free thiol group capable of interacting with the electrophilic group of ROS [130, 131] . Its principal antioxidant mechanism of action, however, is the indirect one, as precursor of GSH, one of the most important intracellular antioxidant agents.
GSH is a tripeptide formed from glutamic acid, cysteine and glycine, synthesized in the cell cytoplasm, in a manner dependent on the cellular availability of cysteine and on the activity of the enzyme glutamate cysteine ligase (GCL) [132] ; NAC can easily cross the cellular membrane and inside the cell it is deacetylated to cysteine, used for the synthesis of GSH [130] . The intracellular entry of the NAC at the level of the central nervous system is mainly linked to the amino acid transporter C1 (ECAAC1) and, in the astrocytes, also to the cystine/glutamate (Xc-) antiporters; [133] through the latter, NAC derived cysteine can lead to an increased glutamate release from the astrocytes, that permits the activation of the Gi-coupled metabotropic glutamate receptors, with subsequent influence also on dopamine release [133, 134] .
Furthermore, some studies have shown that NAC is able to reduce neuroinflammation probably inhibiting microglia and the production of proinflammatory cytokines and oxidative species by the same. [135] The discovery of the influence of NAC on oxidative stress, neuroinflammation and monoamine transmission has increased the interest to its use in the treatment of neuropsychiatric disorders, as all these mechanisms are involved in their pathogenesis. In recent years, several clinical trials have been conducted on these disorders using NAC as adjunctive treatment and the results were generally positive, although the data are still limited.
Among the psychiatric disorders examined there are addiction, schizophrenia, bipolar disorders, obsessive compulsive and related disorders, as trichotillomania, skin-picking and nails biting [131] ; after a trial on patients with substance abuse and post traumatic stress disorder (NCT02499029) [136] , another trial on posttraumatic stress disorders is currently recruiting patients (NCT01664260) [137] .
With regard to the topic of interest of this article, Strawn and Saldaña reported the case of a 17 year boy with GAD and social phobia, affecting the normal proper functioning of the person, only partially responding to treatment with high doses of sertraline; the addition to therapy of NAC 1200 mg twice a day was followed by significant improvement of both psychic and somatic anxiety symptoms [138] . A preclinical study on zebrafish has shown that NAC prevented the anxietylike behaviours induced by an acute stressor and thus, numerous studies have been conducted to evaluate the preventive or therapeutic effect of selenium replacement therapies [142] .
Selenium has antioxidant property, both by itself and through its metabolites, but their short half life limits the possibility of quantifying their therapeutic effectiveness [143] . It can act as a cofactor for some antioxidant enzymes, such as GPx and to take advantage of this property different organoselenium compounds have been recently developed [144] ; these include diphenildiselenide, which has been shown to reduce anxiety-like behaviour in EPM and in contextual fear condition in rats treated with monosodium glutamate [145] .
A clinical study on selenium supplementation in HIV/AIDS affected patients has shown that, after 12 months, treated patients reported less anxiety compared to the control group, suggesting that it could be useful in these patients to alleviate the anxiety associated with the disease [146] .
Synthetic antioxidants 4.6.1 Edaravone
Edaravone is an antioxidant molecule developed in Japan and commercialized in Japan and India. It acts as a direct antioxidant by scavenging ROS and it is used for its anti-cytokine and neuroprotective action in amyotrophic lateral sclerosis. It is considered an orphan drug [147] and in a phase II study has been demonstrated a slower decline in patient treated with edaravone [148] , although its efficacy has not been completely demonstrated, according to a recent study [149] . Edaravone has been also used in cardiovascular disease and in the prevention of atherosclerosis for its capacity to reduce lipid peroxidation and monocyte adhesion to vascular endothelium.
Edaravone has been tested in a model of anxiety in rats induced by the administration of bacterial lipopolysaccharide; its administration could revert the anxiety-like response in the EPM. [150] In a model of chronic restrain stress, edaravone could ameliorate the oxidative stress response measured by enzyme activity and glutathione concentration in hippocampus and prefrontal cortex and it could also reverse the anxiety-like behaviour in the EPM [151] , suggesting an effect exerted essentially by neuroprotection.
MitoQ
MitoQ is the most characterized mitochondrial acting compound and is composed by a quinone linked to a triphenylphosphonium (TTP) with an alkyl chain [152] .
This compound exerts its effect passing the mitochondrial membrane, due to the TTP moiety, which permits an accumulation in the mitochondria [152] .
After passing the membrane the quinone moiety is converted by the succinate dehydrogenase in the active antioxidant form of ubiquinol, which detoxifies ROS yielding H-ion and it is than converted in ubiquinone.
Succinate dehydrogenase converts the ubiquinone in ubiquinol, permitting the recycling of the antioxidant and blocking the lipid peroxidaxion [153] . Furthermore, the reduced form ubiquitinone is slowly oxidized by the complex III, switching the reaction to succinate dehydrogenase and increasing the antioxidant efficacy [154] .
MitoQ has been tested in animal models of neurological diseases such as Hungtington Disease [155] and in a phase 2 trial on Parkinson disease [156] .
In a recent study by Nussbaumer et al MitoQ has been
shown to reduce anxiety-like behaviour in genetically modified HAB-mice but not in LAB-mice, suggesting a selectivity for anxiety disorder [157] . Although these results are interesting, the effectiveness of MitoQ should be analysed in other anxiety models, for example using non inbred mice, and the response difference between HAB and LAB mice should be clarified on a greater sample.
Minocycline
Minocycline is a second generation tetracycline derivative, introduced as an antimicrobial agent in 1967 [158, 159] , which can also be considered belonging to the class of phenolic antioxidants, for the presence in its molecule of a mulch-substituted phenolic ring, similar to that of ɑ-tocopherol [160] . Minocycline can pass the BEE and exerts neuroprotective effect by different mechanisms, beyond the antioxidant one [161] . It has an anti-apoptotic effect, either in a caspase-dependent or in a caspase-independent manner: it reduces the release of pro-apoptotic factors from the mitochondria and increases the release of anti-apoptotic factors. It reduces inflammation, for example by suppression of microglial activation, inhibition of pro-inflammatory cytokines and inhibition of MMPs. Furthermore, minocycline can modulate the glutamatergic transmission, probably acting on the kinurenine pathway and thus reducing the production of the NMDA agonist QUIN; it can also act indirectly on the monoamine system [162] .
Given its targets, minocycline has been studied for its possible use in psychiatric disorders. In 1996, Levine wrote a case report that suggested the possible antidepressant effect of minocycline in a patient with catatonic schizophrenia [163] . Then the antidepressant effect of minocycline has been studied though animal models as the Forced Swimming Test (FST) [164] . It has also been proven to be effective in improving cognitive deficits in a murine model of schizophrenia, achieved by administration of phencyclidine [165] .
Furthermore, animal studies have also suggested that minocycline can act on anxiety symptoms [166] . In preclinical studies, melatonin has been observed to reduce oxidative stress in coadministration with buspirone in a model of contention stress [179] . (particularly early life experiences) and social context [185] , whereas most of preclinical data were obtained in normal rats or mice exposed to a conflicting situation (e.g., light-dark box or elevated plus maze) or exposed to natural threats (in which fear response can be considered as defensive, and, therefore, "physiological"). According to some Authors oxidative stress and anxiety in humans might be associated without a clear cause-effect relationship [186] .Perhaps several clinical studies with antioxidants did not produce positive results because there other factors contributing to the pathogenesis of anxiety are insensitive to antioxidants [187] .Another possibility is that ROS in humans may be physiologically important [187] , and the broad-spectrum antioxidant drugs used in clinical studies do not distinguish between physiological and pathological actions of ROS and other oxidative species.
Other limiting factors in human studies are the route of administration and the doses and time of administration of antioxidants, which may not reach the clinically effective concentrations in the CNS [187] .It is always difficult to find a right dose of an antioxidant in humans, which maintains an optimal risk-to-benefit ratio by restraining the toxic effects of ROS without interfering with their physiological activity [188] .Last, but not least, the inclusion criteria in clinical studies did not take into account the presence of specific biomarkers of oxidative stress [187] .
Despite these potential limitations of human studies, the evidence of efficacy of some oxidative stress modulators in rodents is encouraging and further stimulate translational research.
Interestingly, some putative oxidative stress modulators produce anxiolytic effect via mechanisms other than a classical antioxidant mechanism. NAC, for example, activates the cysteine-glutamate antiporter leading not only to an increase in intracellular cysteine (and, therefore, to GSH synthesis), but also to an increase in extracellular glutamate. This in turn activates type-2 metabotropic glutamate receptors in the preterminal region of the axon, thereby reducing glutamate release from nerve terminals [189] . Of note, mGlu2 receptors are targets for the treatment of anxiety and drug addiction [190, 191] .
We believe that the development of an oxidative stress-modulating therapy in anxiety disorders 
